select trial semaglutide cardiovascular outcomes non-diabetic 2023 The - A New Era in Obesity and Care Semaglutide Improves Cardiovascular Outcomes in

Although the FLOW trial and the secondary analysis of the SELECT trial have demonstrated important kidney benefits of semaglutide, the kidney-protective effects of other GLP-1 receptor agonists are less well known, as there have not been prospective trials with kidney outcomes, and it is unclear whether the benefits of these medications are a class effect or are medication specific

Even if you were on the maximum 2.4mg of semaglutide, you start tirzepatide at 2.5mg

If you're uncomfortable with any changes you're experiencing, talk to your healthcare provider to help guide your next steps

For once-weekly injections, selecting a day when you have time to manage the injection calmlysuch as a weekend morningcan reduce stress and improve technique